Work

Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Year: 2006

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v108.11.2733.2733

Authors: Madeleine Duvic, Youn Kim, Sunil Reddy, Andres Forero-Torres, Lauren C. Pinter-Brown, Mark U. Rarick, John Zic, Sophie Worobec, Neil Korman, Timothy Kuzel, Kimberly Bohjanen, Karen Flessland, Jeremy Barton, Eric Sievers

Institutions: The University of Texas MD Anderson Cancer Center, Stanford University, University of Alabama at Birmingham, University of California, Los Angeles, Kaiser Permanente, Vanderbilt University, University of Illinois Chicago, University Hospitals of Cleveland, Northwestern University, University of Minnesota, Seagen (United States)

Language: English

Topic: Cutaneous lymphoproliferative disorders research

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2557644044

FWCI: 2.118

Cites:

Cited by: 8

Related to: 10